Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3711687 | 0.86 | SLC6A9 (0.43) | SLC6A9SLC6A5OXTR | |
| SCHEMBL13949277 | 0.82 | SLC6A9 (0.45) | MAPTCTSSCTSKSLC6A9SLC6A5 | |
| SCHEMBL7894548 | 0.79 | OPRD1 (0.32) | SLC6A9SLC6A5OXTR | |
| SCHEMBL3711967 | 0.79 | OPRD1 (0.32) | SLC6A9SLC6A5OXTR | |
| SCHEMBL7899345 | 0.76 | SLC6A9 (0.64) | SLC6A9SLC6A5 | |
| SCHEMBL7896421 | 0.76 | SLC6A9 (0.64) | SLC6A9SLC6A5 | |
| SCHEMBL7894745 | 0.76 | SLC6A9 (0.64) | SLC6A9SLC6A5 | |
| SCHEMBL4243958 | 0.76 | OXTR (0.34) | OXTR | |
| SCHEMBL2605332 | 0.75 | SLC6A9 (0.62) | CTSSCTSKSLC6A9SLC6A5 | |
| SCHEMBL2605333 | 0.75 | SLC6A9 (0.62) | CTSSCTSKSLC6A9SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010087761-A1 | 2-AZA-BICYCLO[2.2.2]OCTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-08-05 | — | — | WO | disclosed |
| US-20090030033-A1 | Novel Compounds 894 | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030033-A1 | Novel Compounds 894 | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030033-A1 | Novel Compounds 894 | AZI2, TPMT, AMPD2 | MAPT 1881/4885CTSS 1846/4885CTSK 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.